GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Kemas kini terakhir: 29 Dec, 2025, 12:02PM

124.42

-0.28 (-0.22%)

  • 1H -0.22%
  • 5H 0.06%
  • 1B -0.62%
  • 6B 9.56%
  • Tahun Ke Tarikh 2.32%
  • 1T 33.90%
  • 5T 82.54%
Penutupan Terdahulu 124.70
Buka 124.78
Jumlah Dagangan 955,685
Purata Dagangan (3B) 7,389,553
Modal Pasaran 154,381,189,120
Harga / Pendapatan (P/E TTM) 19.26
Harga / Pendapatan (P/E Ke hadapan) 14.20
Harga / Jualan (P/S) 5.42
Harga / Buku (P/B) 7.19
Julat 52 Minggu
88.57 (-28%) — 128.70 (3%)
Tarikh Pendapatan 10 Feb 2026
Hasil Dividen (DY TTM) 2.54%
Margin Keuntungan 20.76%
Margin Operasi (TTM) 38.49%
EPS Cair (TTM) 4.76
Pertumbuhan Hasil Suku Tahunan (YOY) -0.30%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 24.80%
Jumlah Hutang/Ekuiti (D/E MRQ) 130.79%
Nisbah Semasa (MRQ) 1.37
Aliran Tunai Operasi (OCF TTM) 10.37 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 9.99 B
Pulangan Atas Aset (ROA TTM) 12.14%
Pulangan Atas Ekuiti (ROE TTM) 32.65%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Bercampur
Drug Manufacturers - General (Global) Menaik Bercampur
Stok Gilead Sciences, Inc. Menaik Menaik

AISkor Stockmoo

0.4
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -0.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal -2.0
Purata 0.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
GILD 154 B 2.54% 19.26 7.19
AMGN 173 B 2.97% 24.80 18.50
AZN 284 B 1.71% 30.63 6.38
SNY 117 B 4.57% 15.70 1.34
BIIB 26 B - 15.93 1.51
GRFS 8 B 1.88% 14.44 1.01

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.10%
% Dimiliki oleh Institusi 89.79%
Julat 52 Minggu
88.57 (-28%) — 128.70 (3%)
Julat Harga Sasaran
105.00 (-15%) — 150.00 (20%)
Tinggi 150.00 (Morgan Stanley, 20.56%) Beli
150.00 (Wells Fargo, 20.56%) Beli
150.00 (JP Morgan, 20.56%) Beli
Median 140.00 (12.52%)
Rendah 105.00 (RBC Capital, -15.61%) Pegang
Purata 138.18 (11.06%)
Jumlah 10 Beli, 1 Pegang
Harga Purata @ Panggilan 122.51
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Morgan Stanley 13 Jan 2026 150.00 (20.56%) Beli 121.76
12 Dec 2025 151.00 (21.36%) Beli 120.40
Citigroup 07 Jan 2026 140.00 (12.52%) Beli 124.35
UBS 07 Jan 2026 145.00 (16.54%) Beli 124.35
Wells Fargo 10 Dec 2025 150.00 (20.56%) Beli 121.34
31 Oct 2025 145.00 (16.54%) Beli 119.79
Truist Securities 24 Nov 2025 140.00 (12.52%) Beli 125.27
03 Nov 2025 145.00 (16.54%) Beli 122.05
Needham 13 Nov 2025 140.00 (12.52%) Beli 125.20
31 Oct 2025 133.00 (6.90%) Beli 119.79
Scotiabank 13 Nov 2025 140.00 (12.52%) Beli 125.20
Cantor Fitzgerald 31 Oct 2025 135.00 (8.50%) Beli 119.79
JP Morgan 31 Oct 2025 150.00 (20.56%) Beli 119.79
RBC Capital 31 Oct 2025 105.00 (-15.61%) Pegang 119.79
TD Cowen 23 Oct 2025 125.00 (0.47%) Beli 120.74
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
06 Jan 2026 Pengumuman OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate
22 Dec 2025 Pengumuman Gilead Sciences to Present at Upcoming Investor Conference
22 Dec 2025 Pengumuman Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
19 Dec 2025 CNBC Nine of the largest pharma companies ink deals with Trump to lower drug prices
19 Dec 2025 Pengumuman Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
18 Dec 2025 Pengumuman Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
15 Dec 2025 Pengumuman Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
09 Dec 2025 Pengumuman Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
07 Dec 2025 Pengumuman Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
06 Dec 2025 Pengumuman Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
06 Dec 2025 Pengumuman Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
24 Nov 2025 Pengumuman Gilead Foundation Commits Over $3 Million to Address Food Insecurity
20 Nov 2025 Pengumuman Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
18 Nov 2025 Pengumuman Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
13 Nov 2025 Pengumuman Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
07 Nov 2025 Pengumuman Gilead Provides Update on Phase 3 ASCENT-07 Study
07 Nov 2025 Pengumuman Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
04 Nov 2025 Pengumuman Gilead Sciences to Present at Upcoming Investor Conferences
03 Nov 2025 Pengumuman Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
31 Oct 2025 Pengumuman Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
30 Oct 2025 Pengumuman Gilead Sciences Announces Third Quarter 2025 Financial Results
23 Oct 2025 Pengumuman Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
Papar semua
Hasil Dividen (DY TTM) 2.54%
Purata Hasil Dividen 5T 3.38%
Nisbah Pembayaran 65.13%
Jangkaan Pembayaran Dividen Seterusnya Mar 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
15 Dec 2025 28 Oct 2025 30 Dec 2025 0.79 Tunai
15 Sep 2025 29 Jul 2025 29 Sep 2025 0.79 Tunai
13 Jun 2025 22 Apr 2025 27 Jun 2025 0.79 Tunai
14 Mar 2025 05 Feb 2025 28 Mar 2025 0.79 Tunai
13 Dec 2024 30 Oct 2024 30 Dec 2024 0.77 Tunai
13 Sep 2024 30 Jul 2024 27 Sep 2024 0.77 Tunai
14 Jun 2024 23 Apr 2024 27 Jun 2024 0.77 Tunai
14 Mar 2024 01 Feb 2024 28 Mar 2024 0.77 Tunai
14 Dec 2023 01 Nov 2023 28 Dec 2023 0.75 Tunai
14 Sep 2023 25 Jul 2023 28 Sep 2023 0.75 Tunai
14 Jun 2023 25 Apr 2023 29 Jun 2023 0.75 Tunai
14 Mar 2023 25 Jan 2023 30 Mar 2023 0.75 Tunai
14 Dec 2022 25 Oct 2022 29 Dec 2022 0.73 Tunai
14 Sep 2022 25 Jul 2022 29 Sep 2022 0.73 Tunai
14 Jun 2022 27 Apr 2022 29 Jun 2022 0.73 Tunai
14 Mar 2022 28 Jan 2022 30 Mar 2022 0.73 Tunai
14 Dec 2021 26 Oct 2021 30 Dec 2021 0.71 Tunai
14 Sep 2021 26 Jul 2021 29 Sep 2021 0.71 Tunai
14 Jun 2021 27 Apr 2021 29 Jun 2021 0.71 Tunai
12 Mar 2021 02 Feb 2021 30 Mar 2021 0.71 Tunai
14 Dec 2020 26 Oct 2020 30 Dec 2020 0.68 Tunai
14 Sep 2020 29 Jul 2020 29 Sep 2020 0.68 Tunai
11 Jun 2020 29 Apr 2020 29 Jun 2020 0.68 Tunai
12 Mar 2020 03 Feb 2020 30 Mar 2020 0.68 Tunai
12 Dec 2019 23 Oct 2019 30 Dec 2019 0.63 Tunai
12 Sep 2019 29 Jul 2019 27 Sep 2019 0.63 Tunai
13 Jun 2019 01 May 2019 27 Jun 2019 0.63 Tunai
14 Mar 2019 01 Feb 2019 28 Mar 2019 0.63 Tunai
13 Dec 2018 24 Oct 2018 28 Dec 2018 0.57 Tunai
13 Sep 2018 24 Jul 2018 27 Sep 2018 0.57 Tunai
14 Jun 2018 30 Apr 2018 28 Jun 2018 0.57 Tunai
15 Mar 2018 05 Feb 2018 29 Mar 2018 0.57 Tunai
14 Dec 2017 25 Oct 2017 28 Dec 2017 0.52 Tunai
14 Sep 2017 25 Jul 2017 28 Sep 2017 0.52 Tunai
14 Jun 2017 01 May 2017 29 Jun 2017 0.52 Tunai
14 Mar 2017 06 Feb 2017 30 Mar 2017 0.52 Tunai
13 Dec 2016 31 Oct 2016 29 Dec 2016 0.47 Tunai
14 Sep 2016 22 Jul 2016 29 Sep 2016 0.47 Tunai
14 Jun 2016 27 Apr 2016 29 Jun 2016 0.47 Tunai
14 Mar 2016 02 Feb 2016 30 Mar 2016 0.43 Tunai
14 Dec 2015 26 Oct 2015 30 Dec 2015 0.43 Tunai
14 Sep 2015 23 Jul 2015 29 Sep 2015 0.43 Tunai
12 Jun 2015 24 Apr 2015 29 Jun 2015 0.43 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 3.16 4 2.58
2024 3.08 4 3.33
2023 3.00 4 3.70
2022 2.92 4 3.40
2021 2.84 4 3.91
2020 2.72 4 4.67
2019 2.52 4 3.88
2018 2.28 4 3.65
2017 2.08 4 2.90
2016 1.84 4 2.57
2015 1.29 3 1.28
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda